UNSPSC 51333106: Asenapine maleate

This classification denotes an antipsychotic agent with the molecular formula C17H16ClNO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU9463U2E2, chemically known as 1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-,(3ar,12br)-rel-, (2z)-2-butenedioate (1:1) but more generally known as asenapine maleate, which bears US NIH Compound Identifier 6440510. The base compound, Asenapine, most often comes in base and maleate forms.

UNSPSC 51333106 Asenapine maleate is a Commodity code that, based on recent state and local procurement activity, appears misaligned with actual buying patterns—the code nominally covers a specific atypical antipsychotic pharmaceutical, but recent opportunities tagged to it involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution, none of which concern asenapine maleate specifically. The mismatch suggests that state and local purchasing offices are using this code as a catch-all placeholder for pharmaceutical and drug-related procurement rather than for the specific drug class the code name indicates. When state and local governments do procure under pharmaceutical codes in this family, they are buying naloxone for community health and overdose-response programs, establishing direct contracting pathways with manufacturers to bypass traditional pharmacy benefit managers, and sourcing generic medications and over-the-counter products through cooperative purchasing consortia for distribution across multiple government facilities.

The issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions). Geographic activity spans Florida, Texas, and the upper Midwest. Recent representative opportunities include Seminole County's IFB60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS Commission's RFI HHS0017013 (due April 3, 2026) exploring direct-to-manufacturer prescription contracting models; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers starting July 1, 2026. The code shows little relevant recent activity for asenapine maleate specifically, and firms targeting pharmaceutical procurement should verify actual commodity codes and scope alignment before pursuing opportunities tagged to this Commodity.